Stocks of AcelRx Pharmaceuticals Inc. (ACRX) are poised to climb above their peers

AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX) stock jumped 3.00% on Friday to $0.21 against a previous-day closing price of $0.20. With 1.09 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.18 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $0.2100 whereas the lowest price it dropped to was $0.2000. The 52-week range on ACRX shows that it touched its highest point at $1.25 and its lowest point at $0.16 during that stretch. It currently has a 1-year price target of $4.25. Beta for the stock currently stands at 0.45.

Do You Know The Best Place To Find Gains In Volatile Markets?

In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.

Click here for full details and to join for free.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ACRX was down-trending over the past week, with a drop of -12.12%, but this was down by -18.58% over a month. Three-month performance dropped to -12.49% while six-month performance fell -51.03%. The stock lost -82.83% in the past year, while it has lost -63.23% so far this year. A look at the trailing 12-month EPS for ACRX yields -0.27 with Next year EPS estimates of -0.14. For the next quarter, that number is -0.07. This implies an EPS growth rate of 38.20% for this year and 39.10% for next year.

Float and Shares Shorts:

At present, 145.62 million ACRX shares are outstanding with a float of 145.00 million shares on hand for trading. On Jul 14, 2022, short shares totaled 11.21 million, which was 7.62% higher than short shares on Jun 14, 2022. In addition to Mr. Vincent J. Angotti as the firm’s CEO & Director, Dr. Pamela Pierce Palmer M.D., Ph.D. serves as its Co-Founder, Chief Medical Officer & Director.

Institutional Ownership:

Through their ownership of 13.76% of ACRX’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 9.82% of ACRX, in contrast to 9.34% held by mutual funds. Shares owned by individuals account for 3.85%. As the largest shareholder in ACRX with 4.30% of the stake, Rock Springs Capital Management L holds 6,329,202 shares worth 6,329,202. A second-largest stockholder of ACRX, D. E. Shaw & Co. LP, holds 3,808,993 shares, controlling over 2.59% of the firm’s shares. The Vanguard Group, Inc. is the third largest shareholder in ACRX, holding 3,420,309 shares or 2.33% stake. With a 1.25% stake in ACRX, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 1,841,806 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 1.13% of ACRX stock, is the second-largest Mutual Fund holder. It holds 1,657,710 shares valued at 0.4 million. Fidelity Extended Market Index Fu holds 0.42% of the stake in ACRX, owning 624,138 shares worth 0.15 million.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Mar 30, 2022, ACRX reported revenue of $442.00k and operating income of -$8.99M. Over the past year, revenue came in at $2.75M while operating income stood at -$35.82M. It generated -$8.67M net income for the quarter, which came to -$34.82M over the last twelve months. The EBITDA in the recently reported quarter was -$7.86M and diluted EPS was -$0.06. EBITDA for the full year was -$30.86M.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ACRX since 2 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With ACRX analysts setting a high price target of $4.00 and a low target of $4.00, the average target price over the next 12 months is $4.00. Based on these targets, ACRX could surge 1804.76% to reach the target high and rise by 1804.76% to reach the target low. Reaching the average price target will result in a growth of 1804.76% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. ACRX will report FY 2022 earnings on 03/09/2023. Analysts have provided yearly estimates in a range of -$0.21 being high and -$0.26 being low. For ACRX, this leads to a yearly average estimate of -$0.23. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. AcelRx Pharmaceuticals Inc. reported -$0.06 EPS against a consensus estimate of -$0.06. The surprise factor in the prior quarter was $0.01. Based on analyst estimates, the high estimate for the next quarter is -$0.06 and the low estimate is -$0.09. The average estimate for the next quarter is thus -$0.07.



Summary of Insider Activity:

Insiders traded ACRX stock several times over the past three months with 1 Buys and 0 Sells. In these transactions, 46,400 shares were bought while 0 shares were sold. The number of buy transactions has increased to 6 while that of sell transactions has risen to 12 over the past year. The total number of shares bought during that period was 788,900 while 141,966 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *